The FDA granted Fast Track and Breakthrough Therapy designations for a product involving NRx Pharmaceuticals and HOPE Therapeutics on August 20, 2025.
2 reports, 1 independent
Updated Aug 20
Gone quiet
- Reports
- 2
- Developments
- 3
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA granted Fast Track and Breakthrough Therapy designations for a product involving NRx Pharmaceuticals and HOPE Therapeutics on August 20, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- FDA granted Fast Track designation to NRX-100 on September 4, 2025.Sub-event
FDA granted Fast Track and Breakthrough Therapy designations for NRx/HOPE on August 20, 2025.1 source
FDA grants Fast Track designation to NRX-100 and NRx plans leadership meeting.1 source
Keep exploring
The entities involved
Related events
- The FDA recommended advancement for a new drug application submitted by a company.
- OS Therapies, Inc. is seeking interim and final review data submissions from regulatory bodies while attending major global investment conferences.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
- FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks.
- Experimental therapies require approval from the FDA.
Coverage
Newest first; wire copies grouped- NewMediaWireNRx Pharmaceuticals (NASDAQ: NRXP) Reports Q2 2025 Results, Highlights Progress Across Lead Programs LOS ANGELES, CA - August 19, 2025 (NEWMEDIAWIRE) - NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-
- NewMediaWireNRx Pharmaceuticals (NASDAQ: NRXP) Receives FDA Fast Track Designation for NRX-100 in Treating Suicidal Ideation in Depression LOS ANGELES, CA - August 14, 2025 (NEWMEDIAWIRE) - NRx Pharmaceuticals (